We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...

Get Instant Summarized Text (Gist) A clinical trial demonstrated that combining chemotherapy with immunotherapy significantly improves treatment outcomes for diffuse large B-cell lymphoma (DLBCL ...

In August 2022, T-Mobile and SpaceX announced a bold plan to expand cellular connectivity across the US with the help of low-orbit satellites. Fast-forward to 2025, and the T-Mobile Starlink ...

Unpublished Observation [202]]), HDAC inhibition – possibly in combination with demethylating agents such as decitabine – and NF-κB inhibition may soon represent an alternative and effective ...

Favorable clinical responses have been demonstrated in cutaneous T-cell lymphoma with emerging evidence of clinical activity in other types of lymphoma and, to date, a good toxicity profile.

SGX301 has led positive results in early-stage CTCL, with over 70% achieving treatment success in the phase 3 FLASH study. The phase 3 FLASH (NCT02448381) study evaluating SGX301 (HyBryte) has shown ...

SAMINDUS.BO Sam Industries Ltd.

Each infusion takes at least 1 hour. Brand name: Poteligeo HDAC inhibitor: This type of medication can stop or kill cancer cells. The FDA has approved two of these medications to treat cutaneous ...